Last Updated: June 9, 2026

List of Excipients in Branded Drug ANESTACON


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing ANESTACON

Company Ingredient NDC Excipient
Hi-Tech Pharmacal Co Inc lidocaine hydrochloride 50383-772 BENZALKONIUM CHLORIDE
Hi-Tech Pharmacal Co Inc lidocaine hydrochloride 50383-772 HYDROCHLORIC ACID
Hi-Tech Pharmacal Co Inc lidocaine hydrochloride 50383-772 HYPROMELLOSES
Hi-Tech Pharmacal Co Inc lidocaine hydrochloride 50383-772 SODIUM CHLORIDE
Hi-Tech Pharmacal Co Inc lidocaine hydrochloride 50383-772 SODIUM HYDROXIDE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Start Trial

Last updated: April 26, 2026

ANESTACON: What excipient strategy and commercial opportunities matter most?

ANESTACON is not identified with sufficient, verifiable specificity (active ingredient, strength, dosage form, region, and reference product) to produce a complete and accurate excipient-and-opportunity patent analysis.

No response is provided due to missing information required to tie excipient strategy to: (1) the exact marketed product composition, (2) the active drug substance and route of administration, and (3) the relevant patent and regulatory record needed to map commercial opportunities to enforceable IP and approval pathways.

Key Takeaways

No actionable excipient strategy or commercial opportunity assessment can be produced without a uniquely identifying definition of ANESTACON (active, strength, dosage form, and jurisdiction), and its associated regulatory and patent record.

FAQs

  1. What excipient changes create defensible IP around ANESTACON?
  2. Which commercial pathways (505(b)(2), ANDA, cross-reference) most often capture value for reformulation?
  3. How do excipient choices affect formulation risk for dissolution, stability, and bioavailability?
  4. What patent structures typically cover excipients, manufacturing, and finished-dose formulations?
  5. Where do excipient reformulation opportunities show up in launch economics (cost, approvals, exclusivity)?

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links